A Case of Acute Myocardial Infarction during Chemotherapy of Advanced Rectal Cancer
Background: Cetuximab, irinotecan, levoforinate, and 5-FU (FOLFIRI) are medicines commonly administered to advanced colorectal cancer patients through chemotherapy. Although this regimen is standardized for recurrent metastatic colorectal cancer, the emerging of myocardial infarction is rare.
Purpose: The purpose of this study was to consider the development of myocardial infarction during the chemotherapy of colorectal cancer.
Methods: A retrospective case study was conducted to one patient. An 80-year-old man who developed acute myocardial infarction was in chemotherapy with cetuximab + FOLFIRI with multiple lung metastases after rectal cancer surgery. Data were collected from the patient’s medical and nursing records as well as the physiological function test results.
Results: Three days after the 38th administration, the patient visited an emergency outpatient mainly with complaints of dyspnea and back pain. Electrocardiogram showed that the lower wall infarction was suspected. The patient was transferred to a specialized cardiovascular hospital. Emergency coronary angiography was performed in the diagnosis of acute myocardial infarction, and percutaneous coronary intervention was performed. The patient was discharged on the 10th of disease day.
Conclusion: In this case, it was thought that cetuximab + FOLFIRI synergistically induced hyper thrombogenicity, coronary plaque erosion, and acute myocardial infarction. It may also be necessary for interventions such as monitoring the risks in daily living by the medical care providers and guidance on risk avoidance behaviors.
- Armstrong, G. (2014). Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol, 1218-1227.
- Elder, R., Neal, C., Davis, B. A., Almes, E., Whitledge, L., & Littlepage, N. (2004). Patient Satisfaction with triage nursing in a rural hospital emergency department. Journal of Nursing Care Quality, 19, 265-268.
- Endo, K., Kato, H., & Matsui, R. (2017). Treatment regimens for cancer chemotherapy. Tokyo: Yodosha.
- Goto, A., Suzuki, K., Hasegawa, Y., Sukawa, Y., Fujii, K., & Nishimura, S. (2010). Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer. Jpn J Cancer Chemother, 37(1), 169-171.
- Ito, H., & Mukai, M. (2018). Onco-cardiology. Tokyo: Bunko-sha.
- Komatsu, Y. (2014). Professional management techniques of gastrointestinal cancers chemotherapy side effect. Tokyo: Medical View.
- Laschinger, H. S., Hall, L. M., Pedersen, C., & Almost J. (2005). A psychometric analysis of the patient satisfaction with nursing care quality questionnaire: an actionable approach to measuring patient satisfaction. Journal of Nursing Care Quality, 20(3), 220 -230.
- Machials, J. P., Sempoux, C., Scalliet, P., Coche, J. C., & Humblet, Y. (2007). Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol, 18(4), 738-744.
- Minami, M. (2010). Cardiovascular side-effects of modern cancer therapy. Circ J, 1779-1786.
- Okamoto, R., & Sasaki, T. (2015). Handbook of Cancer Chemotherapy Side Effects: The Treatment and Prevention Second Edition. Tokyo: Yodosha.
- Pore, N., Jiang, Z., Gupta, A., Cerniglia, G., & Kao, G. D. (2006). EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res, 66(6), 3197-3204.
- Shattell, M. (2004). Nurse-patient interaction: A review of literature. Journal of Clinical Nursing, 13, 714 - 722.
- Shirakawa, T., Kusaba, H., Odashiro, K., & Baba, E. (2011). Retrospective study of 8 patients who developed venous thromboembolism during cancer chemotherapy. HEART, 43(7), 1006-1009.
- Suzuki, H. (2014). Editorial Comment to Okada’s study. HEART, 46(4), 517-518.
- Takahashi, M., Tanaka, Y., Tamura, Y., Yamazoe, M., & Shibata, A. (1999). A case report of simulating acute myocardial infarction associated with cardiotoxicity of anticancer agents. Clinic All-Round, 48(1), 193-196.
- Tsutsumi, T., Ozawa, Y., Kawakami, A., Fujii, H., & Asamoto, H. (1990). Acute myocardial infarction induced by lung cancer chemotherapy with cisplatin and etoposide. Jpn J Cancer Chemother, 17(3), 413-417.
Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Nurse Media Journal of Nursing and Department of Nursing, Faculty of Medicine, Diponegoro University as the publisher of this journal.
Copyright encompasses exclusive rights to reproduce and deliver the article in all forms and media, including reprints, photographs, microfilms and any other similar reproductions, as well as translations. The reproduction of any part of this journal, its storage in databases and its transmission by any forms or media, such as electronic, electrostatic and mechanical copies, photocopies, recordings, magnetic media, etc., will be allowed only with a written permission from Nurse Media Journal of Nursing and Department of Nursing, Faculty of Medicine, Diponegoro University.
Nurse Media Journal of Nursing and Department of Nursing, Faculty of Medicine, Diponegoro University make every effort to ensure that no wrong or misleading data, opinions or statements be published in the journal. In any way, the contents of the articles and advertisements published in Nurse Media Journal of Nursing are sole and exclusive responsibility of their respective authors and advertisers.
The Copyright Transfer Agreement Form can be downloaded by click this link Copyright Transfer Agreement Form. The copyright form should be filled with respect to article and be signed originally and sent to the Editorial Office in the form of original email, or scanned document file (softcopy) to:
Sri Padma Sari (Editor-in-Chief)
Department of Nursing, Faculty of Medicine, Diponegoro University
Jl. Prof. Soedarto, Tembalang, Semarang, Central Java, Indonesia 50275
Telp.: +62-24-76480919; Fax.: +62-24-76486849
E-mail: email@example.com or firstname.lastname@example.org (preferable)